GLSI (Greenwich LifeSciences) ROA %: -271.27% (As of Mar. 2026)


GLSI Greenwich LifeSciences Inc GLSI
33 GF Score
Price $21.53
! 1 Warning Sign
View Full Analysis

What is Greenwich LifeSciences ROA %?

Greenwich LifeSciences GLSI -6.78% 33 ROA % is -271.27% as of Mar. 2026. GuruFocus rates GLSI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,423 Biotechnology companies, Greenwich LifeSciences ranks worse than 97.4% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Greenwich LifeSciences's annualized Net Income for the quarter that ended in Mar. 2026 was $-22.63 Mil. Greenwich LifeSciences's average Total Assets over the quarter that ended in Mar. 2026 was $8.34 Mil. Therefore, Greenwich LifeSciences's annualized ROA % for the quarter that ended in Mar. 2026 was -271.27%.

The historical rank and industry rank for Greenwich LifeSciences's ROA % or its related term are showing as below:

GLSI' s ROA % Range Over the Past 10 Years
Min: -5036.76   Med: -200.48   Max: -12.98
Current: -412.6

During the past 8 years, Greenwich LifeSciences's highest ROA % was -12.98%. The lowest was -5036.76%. And the median was -200.48%.

GLSI's ROA % is ranked worse than
97.4% of 1423 companies
in the Biotechnology industry
Industry Median: -33.07 vs GLSI: -412.60

Greenwich LifeSciences  (NAS:GLSI) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-22.628/8.3415
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-22.628 / 0)*(0 / 8.3415)
=Net Margin %*Asset Turnover
=N/A %*0
=-271.27 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Greenwich LifeSciences ROA % Related Terms


Greenwich LifeSciences ROA % Historical Data

* Premium members only.

The historical data trend for Greenwich LifeSciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenwich LifeSciences ROA % Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROA %
Get a 7-Day Free Trial -16.36 -38.46 -86.87 -314.08 -376.91

Greenwich LifeSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -320.82 -547.99 -479.17 -634.79 -271.27

GLSI vs LRMR, RGNX, PBYI: ROA % Comparison

For the Biotechnology subindustry, Greenwich LifeSciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenwich LifeSciences ROA % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's ROA % distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's ROA % falls into.


GLSI
33GF Score
Greenwich LifeSciences Inc GLSI
ROA % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenwich LifeSciences ROA % Calculation

Greenwich LifeSciences's annualized ROA % for the fiscal year that ended in Dec. 2025 is calculated as:

ROA %=Net Income (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=-19.358/( (4.094+6.178)/ 2 )
=-19.358/5.136
=-376.91 %

Greenwich LifeSciences's annualized ROA % for the quarter that ended in Mar. 2026 is calculated as:

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-22.628/( (6.178+10.505)/ 2 )
=-22.628/8.3415
=-271.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -271.27% mean?
Greenwich LifeSciences (GLSI) has a ROA % of -271.27% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Greenwich LifeSciences and its competitors. According to the industry distribution chart, Greenwich LifeSciences ranks #1386 out of 1423 companies in the Biotechnology industry, placing it in the top 97.4%.
Is Greenwich LifeSciences' ROA % too high?
Greenwich LifeSciences' current ROA % is -271.27%. Based on the distribution chart, Greenwich LifeSciences ranks #1386 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Greenwich LifeSciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' ROA % compare to LRMR and RGNX?
According to the Biotechnology industry distribution chart, Greenwich LifeSciences ranks #1386 out of 1423 companies for ROA %. This places Greenwich LifeSciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Greenwich LifeSciences and its competitors. Greenwich LifeSciences's current ROA % is -271.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current ROA % of -271.27%. The current ROA % is -271.27%. Greenwich LifeSciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current ROA % is -271.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Greenwich LifeSciences Business Description

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
33GF Score

Get the complete analysis for GLSI

ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53
Price